ASX Growth Companies With High Insider Ownership To Watch

Simply Wall St

As the Australian market shows signs of awakening from its September slumber, driven by positive movements in financials and defense sectors, investors are keenly observing growth opportunities amidst fluctuating conditions. In this context, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business; here are three such ASX-listed growth companies worth watching.

Top 10 Growth Companies With High Insider Ownership In Australia

NameInsider OwnershipEarnings Growth
Wisr (ASX:WZR)11.6%91.2%
Pointerra (ASX:3DP)23.4%110.3%
Newfield Resources (ASX:NWF)31.5%72.1%
IperionX (ASX:IPX)18.2%79.7%
Image Resources (ASX:IMA)22.2%92.5%
Findi (ASX:FND)33.6%91.2%
Emerald Resources (ASX:EMR)18.1%35.6%
Echo IQ (ASX:EIQ)18%49.9%
Adveritas (ASX:AV1)18.8%96.8%
Acrux (ASX:ACR)15.1%121.1%

Click here to see the full list of 105 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Mineral Resources (ASX:MIN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Mineral Resources Limited, with a market cap of A$7.64 billion, offers mining services across Australia, Asia, and internationally through its subsidiaries.

Operations: The company's revenue is primarily derived from its mining services segment at A$3.30 billion, followed by iron ore at A$2.33 billion, and lithium at A$601 million.

Insider Ownership: 11.4%

Mineral Resources, with significant insider ownership, is navigating financial challenges while positioned for growth. The company recently priced a US$700 million debt offering to refinance existing obligations, indicating strategic capital management. Despite a substantial net loss of A$904 million and high debt levels, MinRes is exploring asset sales to strengthen its balance sheet. Revenue is forecasted to grow at 9.5% annually, outpacing the Australian market's average growth rate of 5.6%.

ASX:MIN Ownership Breakdown as at Sep 2025

Mesoblast (ASX:MSB)

Simply Wall St Growth Rating: ★★★★★★

Overview: Mesoblast Limited, with a market cap of A$3.16 billion, develops regenerative medicine products across Australia, the United States, Singapore, and Switzerland.

Operations: The company's revenue is primarily generated from the development of its cell technology platform for commercialization, amounting to $17.20 million.

Insider Ownership: 33.8%

Mesoblast's high insider ownership aligns with its growth trajectory, underscored by a recent successful commercial launch of Ryoncil® and plans to expand indications. The company secured US$50 million through convertible notes, reflecting strong insider confidence. Despite reporting a net loss of US$102.14 million for the year, revenue surged to US$17.2 million from US$5.9 million previously. With revenue forecasted to grow at 45.4% annually, Mesoblast is positioned for significant expansion in the Australian market.

ASX:MSB Earnings and Revenue Growth as at Sep 2025

PWR Holdings (ASX:PWH)

Simply Wall St Growth Rating: ★★★★★☆

Overview: PWR Holdings Limited designs, prototypes, produces, tests, validates, and sells cooling products and solutions globally with a market cap of A$828.73 million.

Operations: The company's revenue segments include PWR C&R with A$42.33 million and PWR Performance Products with A$101.83 million.

Insider Ownership: 13.4%

PWR Holdings demonstrates growth potential with high insider ownership, evidenced by expected annual earnings growth of 26.7%, outpacing the Australian market. Despite a decline in net profit margin to 7.5% and reduced sales of A$130.1 million, insider buying has occurred recently, albeit modestly. The company is undergoing leadership changes, with founder Kees Weel transitioning to Non-Executive Chairman post-AGM and a search for a permanent CEO underway, reflecting strategic shifts amidst its expansion efforts.

ASX:PWH Earnings and Revenue Growth as at Sep 2025

Make It Happen

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if Mesoblast might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com